Medical ozone promotes Nrf2 phosphorylation reducing oxidative stress and pro-inflammatory cytokines in multiple sclerosis patients

European Journal of Pharmacology

Volumn 811, Issue , 2017, Pages 148-154

  Delgado Roche, Livan ^a   Riera Romo, Mario ^a   Mesta, Fernando ^b   Hernández Matos, Yanet ^c   Barrios, Juan M ^d   Martínez Sánchez, Gregorio ^e   Al Dalaien, Said M ^f  

^a INSTITUTE OF ANIMAL SCIENCE   (Cuba)

^b UNIVERSIDAD AUTÓNOMA DE CIUDAD JUÁREZ   (Mexico)

^c UNIVERSITY OF HAVANA   (Cuba)

^d Mexican Association of Oxidative Stress   (Mexico)

^e Medical Center Beauty Benefit San Biagio di Osimo   (Italy)

^f MUTAH UNIVERSITY   (Jordan)

Author keywords

CK2 expression; Multiple sclerosis; Nrf2 phosphorylation; Oxidative stress; Ozone therapy; Pro inflammatory cytokines

Indexed keywords

BETA1A INTERFERON; CASEIN KINASE II; CATALASE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; INTERLEUKIN 1BETA; MAGINFERA INDICA EXTRACT; PLANT EXTRACT; SPIREL; SPIRULINA EXTRACT; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIMANG; CYTOKINE; OZONE;

ADULT; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HUMAN; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; OZONE THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; DRUG EFFECT; GENE EXPRESSION REGULATION; INFLAMMATION; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADULT; CASEIN KINASE II; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; OZONE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 85020523667     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2017.06.017     Document Type: Article

References (75)

1. Agúndez, J.A., García-Martín, E., Martínez, C., Benito-León, J., Millán-Pascual, J., Díaz-Sánchez, M., Calleja, P., Pisa, D., Turpín-Fenoll, L., Alonso-Navarro, H., Pastor, P., Ortega-Cubero, S., Ayuso-Peralta, L., Torrecillas, D., García-Albea, E., Plaza-Nieto, J.F., Jiménez-Jiménez, F.J., Heme oxygenase-1 and 2 common genetic variants and risk for multiple sclerosis. Sci. Rep., 6, 2016, 20830.
2. Amedei, A., Prisco, D., D'Elios, M.M., Multiple sclerosis: the role of cytokines in pathogenesis and in therapies. Int. J. Mol. Sci. 13 (2012), 13438–13460.
3. Apopa, L.P., He, X., Ma, Q., Phosphorylation of Nrf2 in the transcription activation domain by Casein Kinase 2 (CK2) is critical for the nuclear translocation and transcription activation function of Nrf2 in IMR-32 neuroblastoma cells. J. Biochem. Mol. Toxicol. 22 (2008), 63–76.
4. Arnold, P., Mojumder, D., Detoledo, J., Lucius, R., Wilms, H., Pathophysiological processes in multiple sclerosis: focus on nuclear factor erythroid-2-related factor 2 and emerging pathways. Clin. Pharmacol. Adv. Appl. 6 (2014), 35–42.
5. Bjelobaba, I., Savic, D., Lavrnja, I., Multiple sclerosis and neuroinflammation: the overview of current and prospective therapies. Curr. Pharm. Des. 23 (2016), 693–730.
6. Bocci, V., Borrelli, E., Zanardi, I., Travagli, V., The usefulness of ozone treatment in spinal pain. Drug Des. Dev. Ther. 9 (2015), 2677–2685.
7. Borrelli, E., Mechanism of action of oxygen ozone therapy in the treatment of disc herniation and low back pain. Acta Neurochir. Suppl. 108 (2011), 123–125.
8. Borrelli, E., Bocci, V., Oxygen ozone therapy in the treatment of chronic obstructive pulmonary disease: an integrative approach. Am. J. Clin. Exp. Med. 2 (2014), 9–13.
9. Canning, P., Sorrell, F.J., Bullock, A.N., Structural basis of Keap1 interactions with Nrf2. Free Radic. Biol. Med. 88 (2015), 101–107.
10. Chora, A.A., Fontoura, P., Cunha, A., Pais, T.F., Cardoso, S., Ho, P.P., Lee, L.Y., Sobel, R.A., Steinman, L., Soares, M.P., Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J. Clin. Invest. 117 (2007), 438–447.
11. Delgado-Roche, L., Fernández, J.R., Álvarez, D.R., Glutathione peroxidase-1 expression is up-regulated by ozone therapy in ApoE deficient mice. Biomed. Aging Pathol. 4 (2014), 323–326.
12. Doshi, A., Chataway, J., Multiple sclerosis, a treatable disease. Clin. Med. 16 (2016), s53–s59.
13. Dranguet, J., Fraga, A., Díaz, M.T., Mallok, A., Viebahn-Hänsler, R., Fahmy, Z., Barberá, A., Delgado-Roche, L., Menéndez, S., Fernández, O.S., Ozone oxidative postconditioning ameliorates joint damage and decreases pro-inflammatory cytokine levels and oxidative stress in PG/PS-induced arthritis in rats. Eur. J. Pharmacol. 714 (2013), 318–324.
14. Ersoy, E., Kuş, C.N., Sener, U., Coker, I., Zorlu, Y., The effects of interferon-beta on interleukin-10 in multiple sclerosis patients. Eur. J. Neurol. 12 (2005), 208–211.
15. Fagone, P., Mangano, K., Quattrocchi, C., Motterlini, R., Di Marco, R., Magro, G., Penacho, N., Romao, C.C., Nicoletti, F., Prevention of clinical and histological signs of proteolipid protein (PLP)-induced experimental allergic encephalomyelitis (EAE) in mice by the water-soluble carbon monoxide-releasing molecule (CORM)-A1. Clin. Exp. Immunol. 163 (2011), 368–374.
16. Fagone, P., Mangano, K., Coco, M., Perciavalle, V., Garotta, G., Romao, C.C., Nicoletti, F., Therapeutic potential of carbon monoxide in multiple sclerosis. Clin. Exp. Immunol. 167 (2012), 179–187.
17. Fagone, P., Patti, F., Mangano, K., Mammana, S., Coco, M., Touil-Boukoffa, C., Chikovani, T., Di Marco, R., Nicoletti, F., Heme oxygenase-1 expression in peripheral blood mononuclear cells correlates with disease activity in multiple sclerosis. J. Neuroimmunol. 261 (2013), 82–86.
18. Ferretti, G., Bacchetti, T., Principi, F., Di Ludovico, F., Viti, B., Angeleri, V.A., Danni, M., Provinciali, L., Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Mult. Scler. 11 (2005), 677–682.
19. Flodströma, M., Welsh, N., Eizirik, D.L., Cytokines activate the nuclear factor κB (NF-κB) and induce nitric oxide production in human pancreatic islets. FEBS Lett. 385 (1996), 4–6.
20. Frohman, E.M., Racke, M.K., Raine, C.S., Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 354 (2006), 942–955.
21. Fuccio, C., Longo, C., Capodanno, P., Giordano, C., Scafuro, M.A., Siniscalco, D., Lettieri, B., Rossi, F., Maione, S., Berrino, L., A single subcutaneous inyection of ozone prevents allodynia and decreases the over-expression of proinflmammtory caspases in the orbito-frontal cortex of neuropathic mice. Eur. J. Pharmacol. 603 (2009), 42–49.
22. Gayo, A., Mozo, L., Suárez, A., Tuñon, A., Lahoz, C., Gutiérrez, C., Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse. J. Neuroimmunol. 85 (1998), 122–130.
23. Ghadiri, M., Rezk, A., Li, R., Evans, A., Luessi, F., Zipp, F., Giacomini, P.S., Antel, J., Bar-Or, A., Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis. Neurol. Neuroimmunol. Neuroinflamm., 4, 2017, e340.
24. Gilgun-Sherki, Y., Melamed, E., Offen, D., The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol. 251 (2004), 261–268.
25. Gonsette, R.E., Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J. Neurol. Sci. 274 (2008), 48–53.
26. Goodin, D.S., Glucocorticoid treatment of multiple sclerosis. Handb. Clin. Neurol. 122 (2014), 455–464.
27. Gopal, S., Mikulskis, A., Gold, R., Fox, R.J., Dawson, K.T., Amaravadi, L., Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies. Mult. Scler., 2017, 1, 10.1177/1352458517690617 (Epub ahead of print).
28. Greco, A., Minghetti, L., Sette, G., Fieschi, C., Levi, G., Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 53 (1999), 1876–1879.
29. Habig, W.H., Pabst, M.J., Jakoby, W.B., Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J. Biol. Chem. 249 (1974), 7130–7139.
30. Haji, A.M., Mofrad, M.R., Schellekens, H., Interferon beta: from molecular level to therapeutic effects. Int. Rev. Cell Mol. Biol. 326 (2016), 343–372.
31. Havrdova, E., Giovannoni, G., Gold, R., Fox, R.J., Kappos, L., Phillips, J.T., Okwuokenye, M., Marantz, J.L., Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur. J. Neurol. 24 (2017), 726–733.
32. Higashi, C., Kawaji, A., Tsuda, N., Hayashi, M., Saito, R., Yagishita, Y., Suzuki, T., Uruno, A., Nakamura, M., Nakao, K., Furusako, S., Yamamoto, M., The novel Nrf2 inducer TFM-735 ameliorates experimental autoimmune encephalomyelitis in mice. Eur. J. Pharmacol. 802 (2017), 76–84.
33. van Horssen, J., Drexhage, J.A., Flor, T., Gerritsen, W., van der Valk, P., de Vries, H.E., Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions. Free Radic. Biol. Med. 49 (2010), 1283–1289.
34. ISCO3, 2014. Guidelines and Recommendations for Medical Professionals Planning to Acquire Medical Ozone Generator. 〈http://www.isco3.org/offdocs.html〉.
35. Itoh, K., Tong, K.I., Yamamoto, M., Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radic. Biol. Med. 36 (2004), 1208–1213.
36. Itoh, K., Mimura, J., Yamamoto, M., Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid. Redox Signal. 13 (2010), 1665–1678.
37. Jernås, M., Malmeström, C., Axelsson, M., Olsson, C., Nookaew, I., Wadenvik, H., Zetterberg, H., Blennow, K., Lycke, J., Rudemo, M., Olsson, B., MS risk genes are transcriptionally regulated in CSF leukocytes at relapse. Mult. Scler. 19 (2013), 403–410.
38. Khan, N., Smith, M.T., Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models. Inflammopharmacology 22 (2014), 1–22.
39. Kieseier, B.C., The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs 25 (2011), 491–502.
40. Kim, K.M., Song, J.D., Chung, H.T., Park, Y.C., Protein kinase CK2 mediates peroxynitrite-induced heme oxygenase-1 expression in articular chondrocytes. Int. J. Mol. Med. 29 (2012), 1039–1044.
41. Krieger, S., Sorrells, S.F., Nickerson, M., Pace, T.W.W., Mechanistic insights into corticosteroids in multiple sclerosis: war horse or chameleon?. Clin. Neurol. Neurosurg. 119 (2014), 6–16.
42. León, O.S., Menendez, S., Merino, N., Castillo, R., Sam, S., Pérez, L., Cruz, E., Bocci, V., Ozone oxidative preconditioning: a protection against cellular damage by free radicals. Mediat. Inflammat. 7 (1998), 289–294.
43. León, O.S., Viebahn-Hänsler, R., López, G., Serrano, I., Hernández, Y., Delgado-Roche, L., Santos, B.T., Oru, G.T., Polo, J.C., Medical ozone increases methotrexate clinical response and improves cellular redox balance in patients with rheumatoid arthritis. Eur. J. Pharmacol. 789 (2016), 313–318.
44. Lev, N., Ickowicz, D., Barhum, Y., Blondheim, N., Melamed, E., Offen, D., Experimental encephalomyelitis induces changes in DJ-1: implications for oxidative stress in multiple sclerosis. Antioxid. Redox Signal. 8 (2006), 1987–1995.
45. Lisak, R.P., Neurodegeneration in multiple sclerosis: defining the problem. Neurology 68 (2007), S5–S12.
46. Lutskii, M.A., Esaulenko, I.E., Oxidant stress in the pathogenesis of multiple sclerosis. Neurosci. Behav. Physiol. 37 (2007), 209–213.
47. Magalhaes, F.N., Dotta, L., Sasse, A., Teixera, M.J., Fonoff, E.T., Ozone therapy as a treatment for low back pain secondary to herniated disc: a systematic review and meta-analysis of randomized controlled trials. Pain Physician 15 (2012), E115–E129.
48. Magesha, S., Chena, Y., Hu, L., Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med. Res. Rev. 32 (2012), 687–726.
49. Martínez-Sánchez, G., Re, L., Rectal administration and its application in ozonetherapy. Int J. Ozone Ther. 11 (2012), 41–49.
50. Martínez-Sánchez, G., Al-Dalain, S.M., Menéndez, S., Re, L., Giuliani, A., Candelario-Jalil, E., Álvarez, H., Fernández-Montequín, J.I., León, O.S., Therapeutic efficacy of ozone in patients with diabetic foot. Eur. J. Pharmacol. 523 (2005), 151–161.
51. Martínez-Sánchez, G., Delgado-Roche, L., Díaz-Batista, A., Pérez-Davison, G., Re, L., Effects of ozone therapy on haemostatic and oxidative stress index in coronary artery disease. Eur. J. Pharmacol. 691 (2012), 156–162.
52. Milo, R., Miller, A., Revised diagnostic criteria of multiple sclerosis. Autoimmun. Rev. 13 (2014), 518–524.
53. Molinari, F., Simonetti, V., Franzini, M., Pandolfi, S., Veiano, F., Valdenasi, L., Liboni, W., Ozone autohemotherapy induces long-term cerebral metabolic changes in multiple sclerosis patients. Int. J. Immunopathol. Pharmacol. 27 (2014), 379–389.
54. Nakaso, K., Nakamura, C., Sato, H., Imamura, K., Takeshima, T., Novel cytoprotective mechanism of antiparkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. Biochem. Biophys. Res. Commun. 339 (2006), 915–922.
55. Neymotin, A., Calingasan, N.Y., Wille, E., Naseri, N., Petri, S., Damiano, M., Liby, K.T., Risingsong, R., Sporn, M., Beal, M.F., Kiaei, M., Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic. Biol. Med. 51 (2011), 88–96.
56. Nguyen, T., Nioi, P., Pickett, C.B., The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 284 (2009), 13291–13295.
57. Nicoletti, F., Di Marco, R., Patti, F., Zaccone, P., L'Episcopo, M.R., Reggio, E., Xiang, M., Nicoletti, A., Reggio, A., Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumor necrosis factor-alpha. Cytokine 12 (2000), 682–687.
58. Paglia, D.E., Valentine, W.N., Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab Clin. Med. 70 (1967), 158–169.
59. Pecorelli, A., Bocci, V., Acquaviva, A., Belmonte, G., Gardi, C., Virgili, F., Ciccoli, L., Valacchi, G., NRF2 activation is involved in ozonated human serum upregulation of HO-1 in endothelial cells. Toxicol. Appl. Pharmacol. 267 (2013), 30–40.
60. Pentón-Rol, G., Martínez-Sánchez, G., Cervantes-Llanos, M., Lagumersindez-Denis, N., Acosta-Medina, E.F., Falcon-Cama, V., Alonso-Ramírez, R., Valenzuela-Silva, C., Rodríguez-Jiménez, E., Llópiz-Arzuaga, A., Marín-Prida, J., López-Saura, P.A., Guillén-Nieto, G.E., Pentón-Arias, E., C-Phycocyanin ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells. Int. Immunopharmacol. 11 (2011), 29–38.
61. Petri, S., Korner, S., Kiaei, M., Nrf2/ARE signaling pathway: key mediator in oxidative stress and potential therapeutic target in ALS. Neurol. Res. Int., 2012, 10.1155/2012/878030.
62. Pi, J., Bai, Y., Reece, J.M., Williams, J., Liu, D., Freeman, M.L., Fahl, W.E., Shugar, D., Liu, J., Qu, W., Collins, S., Waalkes, M.P., Molecular mechanism of human Nrf2 activation and degradation: role of sequential phosphorylation by protein kinase CK2. Free Radic. Biol. Med. 42 (2007), 1797–1806.
63. Pryor, W.A., Squadrito, G.L., Friedman, M., The cascade mechanism to explain ozone toxicity: the role of lipid ozonation products. Free Radic. Biol. Med. 19 (1995), 935–941.
64. Re, L., Mawsouf, M.N., Menéndez, S., León, O.S., Martínez-Sánchez, G., Hernández, F., Ozone therapy: clinical and basic evidence of its therapeutic potential. Arch. Med. Res. 39 (2008), 17–26.
65. Re, L., Martínez-Sánchez, G., Bordicchia, M., Malcangi, G., Pocognoli, A., Morales-Segura, M.A., Rothchild, J., Rojas, A., Is ozone pre-conditioning effect linked to Nrf2/EpRE activation pathway in vivo? A preliminary result. Eur. J. Pharmacol. 742 (2014), 158–162.
66. Sagai, M., Bocci, V., Mechanisms of action involved in ozone therapy: is healing induced via a mild oxidative stress?. Med. Gas. Res. 1 (2011), 1–18.
67. Salem, N.A., Assaf, N., Ismail, M.F., Khadrawy, Y.A., Samy, M., Ozone therapy in ethidium bromide-induced demyelination in rats: possible protective effect. Cell Mol. Neurobiol. 36 (2016), 943–954.
68. Sedlak, J., Lindsay, R.H., Estimation of total protein-bound and non-protein sulfhydryl groups in tissue with Ellmans’ reagent. Anal. Biochem. 25 (1968), 192–205.
69. Trenova, A.G., Slavov, G.S., Manova, M.G., Draganaova-Filipova, M.N., Mateva, N.G., Miteva, L.D., Stanilova, S.A., Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis. Scand. J. Clin. Lab. Invest. 20 (2017), 1–6.
70. Viebahn-Hänsler, R., León, O.S., Fahmy, Z., Ozone in medicine: the low-dose ozone concept-guidelines and treatment strategies. Ozone Sci. Eng. 34 (2012), 408–424.
71. Wiendl, H., Toyka, K.V., Rieckmann, P., Gold, R., Hartung, H.P., Hohlfeld, R., Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J. Neurol. 255 (2008), 1449–1463.
72. Wilson, J.L., Bouillaud, F., Almeida, A.S., Vieira, H.L., Ouidja, M.O., Dubois-Randé, J.L., Foresti, R., Motterlini, R., Carbon monoxide reverses the metabolic adaptation of microglia cells to an inflammatory stimulus. Free Radic. Biol. Med. 104 (2017), 311–323.
73. Witko-Sarsat, V., Frielander, M., Nguyen-Khoa, T., Capeillère-Blandin, C., Nguyen, A.T., Canteloup, S., Dayer, J.M., Jungers, P., Drüeke, T., Descamps-Latscha, B., Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J. Immunol. 161 (1998), 2524–2532.
74. World Medical Association, Declaration of Helsinki-ethical principles for medical research involving human subjects. JAMA, 2013, 2191–2194.
75. Yamazaki, H., Tanji, K., Wakabayashi, K., Matsuura, S., Itoh, K., Role of the Keap1/Nrf2 pathway in neurodegenerative diseases. Pathol. Int. 65 (2015), 210–219.